StoneX Group’s Eledon Pharmaceuticals ELDN Stock Holding History

StoneX Group’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$33.8K	Buy	+11,350	New	+$38.1K	﹤0.01%	1665

Other funds holding ELDN

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Triumph Capital Management Denver, Colorado $573M AUM 15.32% 1-Year Est. Return

Daytona Street Capital Saint Louis, Missouri $141M AUM 14.38% 1-Year Est. Return

Prodigy Asset Management Omaha, Nebraska $335M AUM 5.94% 1-Year Est. Return

Farmers & Merchants Investments Inc Lincoln, Nebraska $4.16B AUM 24.97% 1-Year Est. Return

PW Nova Financial Services Newtown, Pennsylvania $491M AUM 22.36% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

RPGK

Retirement Planning Group (Kansas) Leawood, Kansas $4.01B AUM 11.74% 1-Year Est. Return

Howard Financial Services Dallas, Texas $954M AUM 13.71% 1-Year Est. Return

StoneX Group's ELDN Position: Q3 2026 in Review

StoneX Group opened a new position in Eledon Pharmaceuticals (ELDN) in Q3 2026: 11,350 shares worth $33.8K. The stake represents ﹤0.01% of the portfolio and ranks #1665 among its holdings.

50 funds tracked by Wall St. Rank hold ELDN as of Q3 2026.

StoneX Group held 11,350 shares of Eledon Pharmaceuticals worth $33.8K as of Q3 2026.
Eledon Pharmaceuticals was a new StoneX Group position in Q3 2026.
Eledon Pharmaceuticals made up ﹤0.01% of StoneX Group's portfolio in Q3 2026, its #1665 holding.
50 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2026.

Based on StoneX Group's 13F filing for Q3 2026, filed 3 Nov 2026.